3 new studies link GLP-1 agonist diabetes/obesity drugs to higher stomach paralysis risk.

3 new studies based on large patient records suggest a higher risk of stomach paralysis, or gastroparesis, for people using GLP-1 agonist drugs for diabetes and obesity. These injected medications, such as Wegovy and Zepboun, are in high demand due to their effectiveness in weight loss, but their real-world use has not been scrutinized or published in medical journals, making the data preliminary.

May 20, 2024
5 Articles

Further Reading